Andy Greenfield

Karoline Kan, an Asia health reporter for Bloomberg specializing in biotechnology, and Andy Greenfield, a geneticist at the University of Oxford, dive into China's aggressive push to dominate the biotech industry. They discuss the ethical dilemmas of using gene-edited animals in drug development, highlighting China's rapid advancements and controversial practices. Greenfield shares his personal journey with ALS, emphasizing the urgency of scientific breakthroughs, while examining the effectiveness and moral implications of animal research in the quest for new therapies.

Karoline Kan, a Bloomberg Asia health reporter, and Andy Greenfield, a geneticist from Oxford, delve into China's ambitious biotech drive. They discuss the country’s heavy investments in gene-editing animals to develop therapies, like gene-edited pigs modeling ALS. The conversation highlights ethical challenges, regulatory gaps, and the cultural divide in attitudes toward animal research. They also touch on the low translation rate of animal studies to human therapies and China's growing status as a supplier of lab animals.